MIRA INFORM REPORT

 

 

Report No. :

349275

Report Date :

16.11.2015

 

IDENTIFICATION DETAILS

 

Name :

BLOOM PHARMACEUTICALS (PVT) LIMITED

 

 

Registered Office :

House No. 7, Street No. 2, Chaklal Scheme III, Chaklala Cantt, Rawalpindi

 

 

Country :

Pakistan

 

 

Date of Incorporation :

1991

 

 

Com. Reg. No.:

0024932

 

 

Legal Form :

Private Limited Company

 

 

Line of Business :

Subject is engaged in manufacture & marketing of Pharmaceutical Products.

 

 

No. of Employee :

80

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

No complaints

 

 

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

Pakistan

B1

B1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

PAKISTAN ECONOMIC OVERVIEW

 

Decades of internal political disputes and low levels of foreign investment have led to slow growth and underdevelopment in Pakistan. Agriculture accounts for more than one-fourth of output and two-fifths of employment. Textiles account for most of Pakistan's export earnings, and Pakistan's failure to diversify its exports has left the country vulnerable to shifts in world demand. Official unemployment was 6.9% in 2014, but this fails to capture the true picture, because much of the economy is informal and underemployment remains high. Pakistan's human development continues to lag behind most of the region.. As a result of political and macroeconomic instability, the Pakistani rupee has depreciated more than 40% since 2007. The government agreed to an International Monetary Fund Standby Arrangement in November 2008 to preventa balance of payments crisis, but the IMF ended the Arrangement early because of Pakistan's failure to implement required reforms. The economy has stabilized, it continues to underperform and foreign investment has not returned to levels seen during the mid-2000s, due to investor concerns related to governance, electricity shortages, , and a slow-down in the global economy. Remittances from overseas workers, averaging more than$1 billion a month, remain a bright spot for Pakistan. After a small current account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current account turned to a deficit where it remained through 2014, spurred by higher prices for imported oil and lower prices for exported cotton. In September 2013, after facing balance of payments concerns, Pakistan entered into a three-year, $6.7 billion IMF Extended Fund Facility. The Sharif government has since made modest progress implementing fiscal and energy reforms, and in December 2014 the IMF described Pakistan's progress as "broadly on track." Pakistan remains stuck in a low-income, low-growth trap, with growth averaging about 3.5% per year from 2008 to 2014. Pakistan must address long standing issues related to government revenues and the electricity and natural gas sectors in order to spur the amount of economic growth that will be necessary to employ its growing and rapidly urbanizing population, more than half of which is under 22. Other long term challenges include expanding investment in education and healthcare, adapting to the effects of climate change and natural disasters, and reducing dependence on foreign donors.

 

Source : CIA

 

 

Company name

           

BLOOM PHARMACEUTICALS (PVT) LIMITED

 

 

Full Address       

 

Registered Address

House No. 7, Street No. 2, Chaklal Scheme III, Chaklala Cantt, Rawalpindi, Pakistan

                       

Tel #

92 (51) 5154305, 5154301

Fax #

92 (51) 5154301

Email

bppl@brain.net.pk

 

 

Short Description Of Business

 

a.

Nature of Business      

Engaged in manufacture & marketing of Pharmaceutical Products

b.

Year Established

1991

c.

Registration No.

0024932

 

 

Factory Location

 

Address

30, Phase 1 & 2, Industrial Estate, Hattar, NWFP, Pakistan

Tel #

92 (995) 617340, 617542

Fax #

92 (995) 617542

 

 

Auditors

 

Faisal Latif & Co.

(Chartered Accountants)

Office No. 202, First Floor, Kashif Plaza, G-8 Markaz, Islamabad, Pakistan

 

 

Legal Status

 

Subject Company was established as a Private Limited Company in 1991

 

 

 

Authorized Capital    

Rs. 35,000,000/- divided into 3,500,000 shares of Rs. 10/- each

 

Issued & Paid up Capital

Rs. 32,180,080/- divided into 3,218,008 shares of Rs. 10/- each

 

 

Details of Management

 

Names

Designation

Mr. Ahmed Raza

 

Mrs. Zaib-Un-Nisa

 

Mrs. Parveen Amjad Qureshi

 

Mr. Sajid Zahoor

Chief Executive

 

Director

 

Director

 

Director

 

 

Shareholders                 

 

Names

No. of Shares

Mr. Ahmed Raza

 

Mrs. Zaib-Un-Nisa

 

Mrs. Parveen Amjad Qureshi

 

Mr. Sajid Zahoor

804,502

 

402,251

 

1,206,753

 

804,502

 

 

Associates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

 

A.         Subsidiary

 

None

           

B.         Associated Companies

 

Medwin, Pakistan.

 

 

Business Activities

           

Manufacture & marketing of Pharmaceutical Products by its brand name of ACIMET, ADJEX, ADWIN, ADWOTEX, ALGETIN, AMALAR, AMIDOL, AMVIT, AMZEE, ANXOTEN, APLOX, AUSTA-Z, AUSTACLIN-T, AUSTACUTE, AUSTAGENT, AUSTASALIC, AUSTASCAB, AUSTASONE, BENOL, BLOCEF, BLOMALT, BLOMIC, BLOMINOL, BLOMOX, BLOMOZOL, BLOPRIN, BLOTAZ, BLOXEN, BLOXIB, BLOXIME, BLUFEN, BLUNID, BROVENOL, BURNASIL, CIPSA, CISCAP, CLORIL, CONIL, CYTEN, DEPRANIL, DEWPAN, DIANORM, DICORUM, DIMINOL, DIROSAL, DOXYLIDE, DUETON, ERYMIN, ESAPROL, FABOFEN, FLORAX, FLUNIL, GYNOCARE, GYNOSTIN, HYCOCID, JEXIM, KAMCID, KANACLOR, KANIC, KEVOX, LAPROZ, LAVOMOX, LIRIS, NEPNOP, NORMAGESIC, NUTRICAP-M, OLINZIB, ORVACIN, OTRAMAT, PAROL, PIROC

 

 

Number of Employees

 

80        

 

 

Annual Production Volume

 

The capacity and production of the company’s plant is indeterminable as it is multi-product and involves various processes of manufacturing

 

 

Annual Sales Volume

 

Year

In Pak Rupees

2014

100,000,000/- (Estimated)

 

 

Trade Suppliers (Foreign)

 

YANGZHOU PHARMACEUTICAL CO. LTD, CHINA.

MANGALAM DRUGS & ORGANICS LIMITED, INDIA.

SHIJIAZHUANG PHARMACEUTICAL GROUP, CHINA.

 

 

Customers

 

Mainly Private & Government Hospitals, Pharmacies

 

 

Importing Countries

 

Subject import globally from Companies belongs to China, Korea & India. Its global trade suppliers are Companies related to Pharmaceutical Raw Materials

 

 

Bankers

           

(1) First Women Bank Limited, Pakistan.

(2) Silk Bank Limited, Pakistan.

(3) Citibank N.A., Pakistan.

(4) Bank Alfalah Limited, Pakistan.

(5) Habib Bank Limited, Pakistan.

 

(Total Mortgage obtained PKR 208,244,000/-)

 

 

Memberships

 

Lahore Chamber of Commerce & Industry.(LCCI)

 

 

Foreign Exchange Rates

 

Currency

 

Unit

Pakistani Rupee

US Dollar

1

          Rs. 105.55

UK Pound

1

          Rs. 162.00

Euro

1

          Rs. 114.50

 

 

Comments

 

Subject Company was established in 1991 and is engaged in manufacture & marketing of Pharmaceutical Products. Trade relations are reported as fair. Subject can be considered for normal business dealings at usual trade terms & conditions.

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.66.14

UK Pound

1

Rs.100.55

Euro

1

Rs.71.26

 

 

INFORMATION DETAILS

 

Analysis Done by :

DIV

 

 

Report Prepared by :

ANK

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.